XML 68 R10.htm IDEA: XBRL DOCUMENT
v2.4.0.6

3. OPERATIONS AND FINANCING | 12 Months Ended
--- | ---
Sep. 30, 2012
Notes to Financial Statements |
3. OPERATIONS AND FINANCING | The Company has incurred significant costs since its inception in connection with the acquisition of certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities, and clinical trials. The Company has funded such costs with proceeds from the public and private sale of its common and preferred stock. The Company will be required to raise additional capital or find additional long-term financing in order to continue with its research efforts. To date, the Company has not generated any revenue from product sales. The ability of the Company to complete the necessary clinical trials and obtain Federal Drug Administration (FDA) approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company is currently running a large multi-national Phase III clinical trial for head and neck cancer with its partners TEVA Pharmaceuticals and Orient Europharma. CEL-SCI believes that it has enough capital to support its operations for more than the next twelve months and believes that it has ready access to new equity capital should the need arise. To finance the study beyond the next 12 months, the Company plans to raise additional capital in the form of corporate partnerships, debt and/or equity financings. The Company believes that it will be able to obtain additional financing since Multikine is a Phase III product designed to treat cancer and because it has done so consistently in the past. However, there can be no assurance that the Company will be successful in raising additional funds or that funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, the Company will either have to slow down or delay the Phase III clinical trial or even significantly curtail its operations until such time as it is able to raise the required funding. The Company’s expenditures for fiscal year 2012 included several non-recurring items that amounted to approximately $5 million dollars, which were the settlement payments related to the lawsuit (see Note 13) through March 2012, will not recur in fiscal year 2013, thereby reducing the Company’s expenditures. On December 4, 2012, the Company raised another $10.5 million from several institutional investors. The Company has agreed to pay Chardan Capital Markets, LLC, the placement agent for this offering, a cash commission of $682,500 (see Note 17). Since the Company launched its Phase III trial for Multikine, the Company has spent approximately $7,000,000 as of September 30, 2012 on direct costs for the Phase III clinical trial. The total net cost remaining of the clinical trial is estimated to be about $25,000,000. It should be noted that this estimate is only an estimate based on the information currently available in CEL-SCI’s contracts with the Clinical Research Organization responsible for managing the Phase III trial. This number can be affected by the speed of enrollment, foreign currency exchange rates and many other factors, some of which cannot be foreseen today. It is therefore possible that the cost of the Phase III trial will be higher than currently estimated.

X
- Details
Name: | CVM_NotesToFinancialStatementsAbstract
Namespace Prefix: | CVM_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition No authoritative reference available. + References No definition available. + Details
Name: | CVM_OperationsAndFinancingTextBlock
Namespace Prefix: | CVM_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration